내가 좋아할 만한 콘텐츠
T. denticola and F. Nucleatum are known causal pathogens in periodontal disease but they can also exacerbate systemic inflammation and chronic disease. It's time to focus on them. Lets get to work! lnkd.in/gyu-KJe8 #Forsythdentech 2023! #Oral Health #Dental health
Flightpath Biosciences, Inc has been selected to pitch in the Forsyth dentech Pitch Competition! We're excited for the opportunity to present our antimicrobial technology to thought leaders across the oral health innovation ecosystem. Come connect with us at #Forsythdentech 2023.
Congratulations to the Lewis Lab at Northeastern University. This publication and this work will likely change the world for the better and alter the course of Lyme disease in a very positive way. businesswire.com/news/home/2021…
businesswire.com
Flightpath Licenses the First Antibiotic that Selectively Kills Lyme Disease Spirochetes
Flightpath Biosciences, Inc, a biotechnology company advancing microbiome-sparing therapeutics and diagnostics for infectious diseases, licensed a developmen...
UPDATE: We've enrolled >900 participants in largest ever clinical biomarker study of chronic LD. FP is incredibly grateful to the community w/ 200 kits completed already & eGift cards going out shortly. Stay tuned to Lymedisease.org for updates by blog! @lymepolicywonk
UPDATE: We've enrolled >900 participants in largest ever clinical biomarker study of chronic LD. FP is incredibly grateful to the community w/ 200 kits completed already and eGift cards now en route. Stay tuned to LD.org for study updates by blog! @lymepolicywonk
Flightpath Biosciences and partners at LymeDisease (dot) org and Illumina Accelerator are proud to announce the initiation of the largest clinical biomarker study ever conducted in chronic Lyme disease. Please take a look: lymedisease.org/study-chronic-…
Illumina Accelerator welcomes nine exciting new #genomic startups to its second global funding cycle in the U.S. and UK. #IlluminaForStartups bit.ly/39Zms7w
Big news today! Flightpath has been accepted into Illumina Accelerator's Global Class. More to come soon about our study launching March 1st - stay tuned. businesswire.com/news/home/2021…
Congratulations to the Rajadas lab on their recent Nature publication. More evidence that Flightpath's FP-101 development candidate may be effective against multiple drug tolerant strains of Borrelia burgdorferi. We're so proud to be working on #LymeDisease #Flightpath
"Flightpath Biosciences, Inc is Selected to Participate in the Innovation Challenge at RESI Boston 2019" blog.lifesciencenation.com/2019/08/22/mee…
United States 트렌드
- 1. Texas 155K posts
- 2. 3-8 Florida 2,123 posts
- 3. #JimmySeaFanconD1 279K posts
- 4. Reaves 19.5K posts
- 5. #HookEm 10.6K posts
- 6. Sark 5,184 posts
- 7. Jeff Sims 1,689 posts
- 8. Aggies 9,373 posts
- 9. Arch 25.1K posts
- 10. #DonCheadleDay 1,237 posts
- 11. Georgia 49.1K posts
- 12. Life is 10% 2,614 posts
- 13. Marcel Reed 4,474 posts
- 14. Elko 3,062 posts
- 15. Arizona 32.3K posts
- 16. #LakeShow 3,720 posts
- 17. Katie Miller 2,587 posts
- 18. Sylus 96.3K posts
- 19. Banana Fish 9,814 posts
- 20. Kentucky and Mississippi State N/A
내가 좋아할 만한 콘텐츠
-
Lyme Disease Biobank
@LymeBiobank -
Tick Boot Camp
@TickBootCamp -
Bay Area Lyme Foundation
@BayAreaLyme -
Kris Newby
@krisnewby -
Texas Lyme Alliance
@TexasLyme -
Lorraine Johnson, JD/MBA
@lymepolicywonk -
Richard Brooke-Powell
@RichardBrookeP2 -
Lyme Morgellons
@LymeMorgellons -
Andrea Lyme
@AJackso63831215 -
Morgellons Survey
@morgellonsinfo -
Wendy Phillips
@wendyyphillips -
Wendy Adams
@adamswendya -
Phyllis Mervine
@PhyllisMervine
Something went wrong.
Something went wrong.